Team

Guido Gualdoni holds both an MD and a PhD degree in Immunology from the Medical University of Vienna. He is Co-Founder and Chief Executive Officer of G.ST Antivirals and has discovered the potential of 2-deoxyglucose against rhinovirus infections. He has authored numerous publications in international top journals.

Anna-Dorothea Gorki is an expert in respiratory tract infections trained at the Research Center of Molecular Medicine (CeMM, Austrian Academy of Sciences) and the Medical University of Vienna. She holds a PhD degree in Immunology and has (co-)authored numerous publications in international top-journals, including „Cell“.

Dr. Turner is a former Professor of Pediatric Infectious Diseases at the University of Virginia Medical School and is a globally recognized Key Opinion Leader in the field of respiratory viral infections. He has served as the Associate Dean for Clinical Research at UVA, the Head of the Division of Pediatric Infectious Diseases at the Medical Univ. of South Carolina, served as a reviewer of multiple scientific journals including JAMA, New England Journal of Medicine and Clinical Infectious Diseases. He has published over 140 articles, reviews and book chapters and served as a consultant to many companies researching respiratory viral infections. He received his BS in Chemistry from Southern Illinois University and MD from the Southern Illinois University Medical School.

Snezana Radivojev is experienced the development of inhaled formulations and in studying their biopharmaceutics. Her training was based on international cooperations between academia and industry, and her passion is to bridge the translational gap between them. She holds a PhD degree from Medical University of Graz and has (co)authored numerous publications in internationally recognized journals.

Joachim Seipelt holds a PhD degree in Biochemistry and has over 20 years of experience in biotech project evaluation, management, funding, cooperation and licensing.

Alexander joined IST cube in 2018 as Partner. He has more than 15 years of experience in management consulting, eight of which with McKinsey & Company in Vienna and Chicago. His focus has been on strategy, innovation, and M&A in chemicals, materials, agriculture and life science related industries. By education and heart Alexander is a scientist: He studied chemistry at TU Graz, ETH Zurich and the University of Vienna before moving on to become a postdoctoral fellow at Harvard University. From 2013-2015 he was a part time research fellow at IIASA (International Institute for Applied Systems Analysis), a leading European Thinktank.

Johannes Stöckl holds a PhD degree in Immunology from the Medical University of Vienna. He has more than 20 years of experience as a successful group leader in the field of Immunology and Rhinovirus research. He is Co-Founder of G.ST Antivirals.

Dr. Deschatelets is a serial entrepreneur based in Massachusetts. He has co-founded Apellis Pharmaceuticals in November 2009 and has served as its chief scientific officer since. Prior to founding Apellis, Dr. Deschatelets co-founded Potentia Pharmaceuticals and was its chief operating officer when the company signed a licensing agreement with Alcon in 2009 for Potentia’s ocular drug development program. Dr. Deschatelets has been engaged in state-of-the-art research in the areas of surface chemistry and organic synthesis for the last 25 years, and he was a co-founder of Syntetica Fine Chemicals, a custom chemical synthesis company supporting the pharmaceutical industry. Dr. Deschatelets received his PhD degree in organic chemistry from the University of Montreal and his postdoctoral training in the laboratory of Dr. George Whitesides at Harvard University.

Theodore J. Lampidis is a renowned expert in cancer research at the University of Miami’s Sylvester Comprehensive Cancer Center. He has pioneered the field of 2-deoxyglucose research over the past 20 years and has contributed to several scientific breakthroughs in basic, translational and clinical aspects of the drug.